On April 9, 2024 AffyImmune, a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, affinity-tuned CAR T cell therapies, reported preclinical data on new indications for its lead program, AIC100, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2024 (Press release, AffyImmune Therapeutics, APR 9, 2024, View Source [SID1234641964]). The data showcases the efficacy of AIC100 in non-small cell lung cancer (NSCLC) and cervical cancer in preclinical models expressing cell surface ICAM-1.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Affinity tuned AIC100 is expected to selectively bind and kill tumor cells expressing cell surface ICAM-1 while sparing healthy cells.
The preclinical studies demonstrated that AIC100 exhibited potent cytotoxic activity against ICAM-1-positive NSCLC and cervical cancer cell lines in vitro, resulting in 100% cell death within 72 hours. The investigational affinity-tuned CAR T candidate AIC100 also demonstrated remarkable efficacy in NSCLC and cervical cancer xenograft models, with the active arm showing a significant reduction in tumor size and an increase in survival compared to placebo.
"We are excited to share preclinical proof-of-concept data for our affinity-tuned CAR T program AIC100 in new solid tumor types. Advanced stage cervical cancer and NSCLC represent significant unmet medical needs, with patients experiencing poor outcomes and a 5-year survival rate ranging from approximately 10 to 20%," said Matt Britz, CEO, AffyImmune. "These preclinical data build on the potential for AIC100 to be a first-in-class targeted therapy for ICAM-1-positive solid tumors with significant unmet medical need."
"Advanced lung and cervical cancers continue to have unmet medical need despite our recent advances in targeted and immune therapy. There are few good options for patients who experience progression after initial therapy for metastatic disease," said Jorge J. Nieva, MD, Associate Professor of Clinical Medicine, Keck School of Medicine, University of Southern California. "This promising preclinical data presented at AACR (Free AACR Whitepaper) 2024 suggest that AIC100 could be a potential new option for patients with these ICAM-1-positive tumors."
AIC100 is currently in Phase 1 trials for anaplastic and poorly differentiated thyroid cancer (NCT04420754).